PURE BIOSCIENCE, INC.

PURE Bioscience, Inc.

Overview

PURE Bioscience develops and commercializes Silver Dihydrogen Citrate (SDC)–based antimicrobial products for pathogen and hygiene control. Its platform produces colorless, odorless, non-toxic, non-caustic antimicrobials with high bioavailability and low environmental impact. SDC is claimed to be broad-spectrum and resistant development by bacteria has not been observed.

Core technology

• Platform: stabilized ionic silver (Silver Dihydrogen Citrate, SDC).
• Key attributes: broad-spectrum antimicrobial action; colorless, odorless, non-toxic, non-caustic; high bioavailability; low environmental impact.

Primary products and applications

• PURE® Hard Surface Disinfectant and Sanitizer (Ready to Use)

  • EPA-registered for hard surfaces, including food contact surfaces.
  • Rapid kill times, down to 30 seconds for many organisms (examples: MRSA, Norovirus, SARS-CoV-2, E. coli, Salmonella, Listeria).
  • Non-toxic, non-caustic, odorless; no rinsing or PPE required for specified uses.
  • Coverage in application systems: up to 40,000 cubic feet per gallon.

• PURE® Control® (direct food contact processing aid)

  • FDA approvals: FCN 1768 (poultry processing) and FCN 1600 (produce processing).
  • For poultry, demonstrated reductions up to 6-log for Salmonella with no impact on yield; no label declaration required for produce or poultry.
  • Not approved for on-line (OLR) poultry processing at this time; approvals for other raw meats are not guaranteed.

• SILVÉRION® (raw material ingredient)

  • Patented SDC-based antimicrobial formulation used as an active ingredient or preservative in personal care products.
  • Sold domestically and internationally in various personal care formulations.

• Other SDC-based products

  • PURE® Multi-Purpose Hi-Foam Cleaner Concentrate: dilutable, high-foaming cleaner with SDC.
  • PURE® Multi-Purpose and Floor Cleaner: dilutable cleaner for food processing and other facilities incorporating SDC.
  • Additional end-use SDC products, SDC-preserved products, and SDC sold as a raw material for manufacturing.

Markets and end users

• Food processing: harvesting equipment, grow barns, processing facilities.
• Food service and hospitality: restaurants, quick-serve restaurants, hotels, supermarkets.
• Healthcare: hospitals, assisted living facilities, clinics.
• Facility care: daycare centers, schools, offices, commercial buildings.
• Transportation: ground, rail, air, and marine sanitation.
• Personal care: cosmetic and personal care product formulations using SILVÉRION 2400.

Intellectual property and regulatory

• Intellectual property: 12 U.S. patents related to SDC technology; trademarks include PURE Bioscience, PURE, SILVÉRION, Powered by SDC Ag+, and PURE Control.
• Regulatory oversight:
  • EPA regulates disinfectant/sanitizer products under FIFRA; state registrations and fees may apply.
  • FDA and USDA involvement for certain food processing applications (e.g., PURE Control).
  • Health Canada registrations for disinfectants and antimicrobial food processing aids; EU considerations for cosmetics/personal care.
• International approach: products sold under company or distributor registrations, with ongoing or planned foreign registrations through partners or direct filings.

Sales, customers and distribution

• Sales model: direct sales to end users and through a growing distributor network.
• Fiscal year ended July 31, 2026:
  • Net product sales: $2,315,000.
  • Top three customers: $824,000 of net product sales.
  • One customer represented 24% of net product sales.
  • No foreign sales reported for the 2026 period.
• Distribution strategy: expand distributor network and partner on international approvals and market access.

Financial snapshot (fiscal year ended July 31, 2026)

• Revenue and profitability:
  • Net product sales: $2,315,000 (2026); $2,198,000 (2025).
  • Net revenue: $2.32 million (2026).
  • Net loss: $2.5 million (2026); $2.4 million (2025).
  • Cumulative net loss: approximately $141.5 million to date.
• Cash and liquidity:
  • Cash balance: $569,000 as of July 31, 2026.
  • Operating cash used: $1.7 million for the year ended 2026.
• Financing:
  • Private placement and convertible debt financing in fiscal 2026 with net proceeds of approximately $4.0 million.
  • Convertible promissory notes outstanding: $5.8 million (convertible at VWAP between $0.07 and $0.23 per share).
• Capitalization:
  • Shares outstanding or reserved for issuance (as of October 29, 2026): 203,648,232.
  • Authorized capital stock: 250,000,000 shares of common stock; 5,000,000 shares of preferred stock.

Operations and corporate

• Headcount: 10 full-time and 1 part-time employees (as of October 29, 2026).
• Office model: virtual office with remote work arrangements and no physical lease obligations.
• Corporate history: incorporated in California in 1992 as Innovative Medical Services; renamed PURE Bioscience and reincorporated in Delaware in 2011.

Strategic priorities

• Expand distribution and sales channels domestically and internationally.
• Pursue additional regulatory approvals and partner with third parties for market access.
• Develop additional proprietary SDC-based products and product lines.
• Protect and expand intellectual property while using the SDC platform to create new product and revenue opportunities.